首页> 外文期刊>Chemical and Pharmaceutical Bulletin >Discovery and Biological Evaluation of Potent and Orally Active Human 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
【24h】

Discovery and Biological Evaluation of Potent and Orally Active Human 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

机译:有效和口服活性人11β-羟基类固醇脱氢酶1型抑制剂治疗2型糖尿病的发现和生物学评估

获取原文
           

摘要

We synthesized and evaluated novel 5-[2-(thiophen-2-yl)propan-2-yl]-4 H -1,2,4-triazole derivatives as 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors. Optimization of the thiophene ring and the substituents on the 1,2,4-triazole ring produced 3,4-dicyclopropyl-5-{2-[3-fluoro-5-(trifluoromethyl)thiophen-2-yl]propan-2-yl}-4 H -1,2,4-triazole monohydrochloride ( 9a ), which showed potent and selective inhibitory activity against human 11β-HSD1. Compound 9a was also metabolically stable against human and mouse liver microsomes. Oral administration of 9a to diabetic ob/ob mice lowered corticosterone levels in adipose tissue, and thereby reduced plasma glucose and insulin levels in a dose-dependent manner.
机译:我们合成并评估了新型5 [2-(噻吩-2-基)丙-2-基] -4 H -1,2,4-三唑衍生物,作为1β-羟基甾类脱氢酶1型(11β-HSD1)抑制剂。噻吩环和1,2,4-三唑环上的取代基的优化产生了3,4-二环丙基-5- {2- [3-氟-3-(三氟甲基)噻吩-2-基]丙烷-2- yl} -4 H -1,2,4-三唑一盐酸盐(9a),对人11β-HSD1具有强效和选择性的抑制活性。化合物9a对人和小鼠肝微粒体也具有代谢稳定性。对糖尿病ob / ob小鼠口服9a可以降低脂肪组织中的皮质酮水平,从而以剂量依赖的方式降低血浆葡萄糖和胰岛素水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号